Arctic Vision to acquire MDCO Technology’s ophthalmic device business

Core Insights - Arctic Vision has signed an agreement to acquire the ophthalmic device business of MDCO Technology, integrating MDCO's intraocular lens, implantable contact lens, and refractive device platforms into its global innovation framework for ophthalmic solutions [1][2]. Group 1: Acquisition Details - The acquisition aims to enhance Arctic Vision's capabilities by combining MDCO's advanced device engineering and manufacturing with its existing R&D in therapies, aligning with its strategy to expand its pipeline in areas with significant unmet needs in the ophthalmic sector [2][3]. - Following the acquisition, MDCO will operate as a wholly owned subsidiary of Arctic Vision, allowing for a more integrated approach to product development and market reach [3]. Group 2: Operational Structure - The combined group will maintain operations in three locations: Shanghai for biopharmaceutical research and regulatory affairs, Hangzhou for device R&D, manufacturing, and commercial management, and California for design and global collaboration [4]. - MDCO specializes in cataract and myopia-correction solutions, leveraging nearly two decades of expertise in materials science and precision moulding, with its Hangzhou site serving as the center for operations [4]. Group 3: Strategic Vision - Arctic Vision's founder, Dr. Eddy Wu, stated that this transaction represents a pivotal step for the company's long-term growth strategy, establishing a comprehensive ophthalmic innovation ecosystem that integrates scientific excellence with advanced manufacturing and commercial scale [5]. - The company is positioning itself for broader global investment participation and future capital-market opportunities, aiming to expand its ability to reach more patients and deliver greater impact across the ophthalmology community worldwide [6].